IN THE NEWS
Cardiac Science and GEMMS Announce Co-Marketing Agreement
Successful Installation of Combined Products Completed at 27-Physician Heart Center ArkansasBOTHELL, WA – Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, announced today that it has signed a non-exclusive marketing agreement with Gateway Electronic Medical Management Systems (GEMMS), the nation's leader in installed and operational electronic medical record systems (EMR) for cardiology practices.
Cardiac Science also announced today that it has successfully completed the first installation of HeartCentrix with GEMMS ONE at Heart Clinic Arkansas (HCA), a 27-physician cardiology practice located in Little Rock.
Under the terms the marketing agreement, GEMMS will recommend Cardiac Science’s HeartCentrix™ software, which enables seamless transfer of ECG, exercise stress and Holter monitoring results to physician EMR software, when it markets its GEMMS ONE solution to cardiology practices that use Burdick and Quinton diagnostic devices. GEMMS ONE is the company’s point-of-service, wireless data collection and documentation system for cardiologists. HeartCentrix can either be installed with a new GEMMS ONE implementation or it can be easily incorporated into an existing GEMMS ONE installed account.
With GEMMS ONE, HeartCentrix streamlines the cardiologist’s office workflow by automating diagnostic testing from order though billing, reducing data transcription errors and providing the physician with a unified view of patient diagnostic data. Physicians will have immediate access to electronically view and edit a patient’s test results and later retrieve the data as soon as it is needed.
GEMMS ONE is widely recognized by cardiologists as a leading EMR solution,” said Garry Norris, Cardiac Science’s vice president for marketing. “And for decades cardiologists have preferred Burdick and Quinton ECGs, Holter devices and stress systems for their superior clinical capabilities, reliability and ease-of-use. By integrating HeartCentrix with GEMMS ONE, Cardiac Science can help cardiology offices work more efficiently by connecting their preferred Burdick and Quinton brand diagnostic devices with their GEMMS EMR for a smoother, more seamless workflow, office-wide, and a greater ROI on their EMR investment. HCA agrees that this is a tremendous value for the cardiologist’s office. We could not be happier with the success of this installation.
The efficiency of our office has significantly improved with the addition of HeartCentrix to our GEMMS ONE system,” said Rhonda Mayo, RN, Clinical/Nursing Supervisor at HCA. “Prior to this implementation, we were still scanning multi-page Stress-Echo and resting ECG test results. Now the results are transferred to the patient’s chart electronically. The process is considerably less time consuming, far less expensive and the images are higher quality.
With HeartCentrix, our GEMMS ONE system now provides immediate access to patient information and we don’t have to worry about losing the hard copy of test results,” said Dr. David Griffen of HCA. “If a patient suddenly presents with chest pain, we can go to his chart immediately for the critical information we need. It’s all right there at our finger tips.
By sharing information and seamlessly integrating our technologies, we can achieve our shared vision to provide cardiologists with complete access to critical patient information,” said GEMMS CEO Rodger P. Pinto, Ph.D. “This enables the cardiologist to make faster, more confident diagnoses and decisions.
Cardiac Science, GEMMS and HCA will present a case study outlining the success of the installation at a breakfast symposium at the American College of Cardiology Annual Scientific Session on Monday, March 26 from 6:00 to 7:00 a.m. in the Steering Room of the Hilton New Orleans Riverside.
About GEMMS
Founded in 1997 and headquartered in Indianapolis, GEMMS designs, implements and supports medical information solutions specifically created for ambulatory cardiology practices. Developed in the nation’s largest cardiology practice, it is the nation's first provider of electronic knowledge technology for cardiology practices. The company’s GEMMS ONE Single-Point Decision System, along with its continuum of integrated information products, are used by more cardiologists than any other system. For more information, call 800.773.3111 or visit www.gemmsnet.com.
About Cardiac Science
Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT
For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif